カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

巣状分節性糸球体硬化症（FSGS）治療のグローバル市場2023：薬物治療、透析、腎移植

■ 英語タイトル：Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR23AG11388）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR23AG11388
■ 発行日：2023年8月
■ 調査対象地域：グローバル
■ 産業分野：医薬品＆ヘルスケア
■ ページ数：100
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[巣状分節性糸球体硬化症（FSGS）治療のグローバル市場2023：薬物治療、透析、腎移植]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Global Info Research社の最新の調査によると、巣状分節性糸球体硬化症（FSGS）治療のグローバル市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。
本調査レポートは、世界の巣状分節性糸球体硬化症（FSGS）治療市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、種類別、用途別に記載されています。

市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。

本資料の主な目的は次のとおりです。
- 世界および主要国の市場機会の規模を決定するため
- 巣状分節性糸球体硬化症（FSGS）治療の成長可能性を評価するため
- 各製品および最終用途市場の将来の成長を予測するため
- 市場に影響を与える競争要因を評価するため

巣状分節性糸球体硬化症（FSGS）治療市場は種類と用途によって区分されます。2018年～2029年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメント
・薬物治療、透析、腎移植

用途別セグメント
・一次性FSGS、二次性FSGS

主要な市場プレーヤー
・Competition Deep Dive、Beckman Coulter Inc.、Baxter International Inc.、ChemoCentryx Inc.、Dimerix Ltd、Medtronic PLC、Pfizer Inc.、Mylan N.V.、Amgen Inc.、AstraZeneca plc

地域別セグメントは次の地域・国をカバーします。
・北米（アメリカ、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、巣状分節性糸球体硬化症（FSGS）治療製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な巣状分節性糸球体硬化症（FSGS）治療メーカーの企業概要、2019年～2022年までの巣状分節性糸球体硬化症（FSGS）治療の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な巣状分節性糸球体硬化症（FSGS）治療メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2018年～2029年までの地域別巣状分節性糸球体硬化症（FSGS）治療の販売量、売上、成長性を示しています。
・第5、6章では、2018年～2029年までの巣状分節性糸球体硬化症（FSGS）治療の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域での巣状分節性糸球体硬化症（FSGS）治療市場予測を収録しています。
・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。
・第13章では、主要な原材料、主要なサプライヤー、および巣状分節性糸球体硬化症（FSGS）治療の産業チェーンを掲載しています。
・第14、15章では、巣状分節性糸球体硬化症（FSGS）治療の販売チャネル、販売業者、顧客、調査結果について説明します。

・市場概要
– 巣状分節性糸球体硬化症（FSGS）治療の概要
– 種類別分析（2018年vs2022年vs2029年）：薬物治療、透析、腎移植
– 用途別分析（2018年vs2022年vs2029年）：一次性FSGS、二次性FSGS
– 世界の巣状分節性糸球体硬化症（FSGS）治療市場規模・予測
– 世界の巣状分節性糸球体硬化症（FSGS）治療生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– Competition Deep Dive、Beckman Coulter Inc.、Baxter International Inc.、ChemoCentryx Inc.、Dimerix Ltd、Medtronic PLC、Pfizer Inc.、Mylan N.V.、Amgen Inc.、AstraZeneca plc
・メーカー別市場シェア・市場集中度
・地域別市場分析2018年-2029年
・種類別分析2018年-2029年：薬物治療、透析、腎移植
・用途別分析2018年-2029年：一次性FSGS、二次性FSGS
・巣状分節性糸球体硬化症（FSGS）治療の北米市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・巣状分節性糸球体硬化症（FSGS）治療のヨーロッパ市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・巣状分節性糸球体硬化症（FSGS）治療のアジア市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・巣状分節性糸球体硬化症（FSGS）治療の南米市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・巣状分節性糸球体硬化症（FSGS）治療の中東・アフリカ市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析）
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Product Overview and Scope of Focal Segmental Glomerulosclerosis (FSGS) Treatment
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Drug Therapy
1.3.3 Dialysis
1.3.4 Kidney Transplant
1.4 Market Analysis by Application
1.4.1 Overview: Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Primary FSGS
1.4.3 Secondary FSGS
1.5 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size & Forecast
1.5.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity (2018-2029)
1.5.3 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Competition Deep Dive
2.1.1 Competition Deep Dive Details
2.1.2 Competition Deep Dive Major Business
2.1.3 Competition Deep Dive Focal Segmental Glomerulosclerosis (FSGS) Treatment Product and Services
2.1.4 Competition Deep Dive Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Competition Deep Dive Recent Developments/Updates
2.2 Beckman Coulter Inc.
2.2.1 Beckman Coulter Inc. Details
2.2.2 Beckman Coulter Inc. Major Business
2.2.3 Beckman Coulter Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Product and Services
2.2.4 Beckman Coulter Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Beckman Coulter Inc. Recent Developments/Updates
2.3 Baxter International Inc.
2.3.1 Baxter International Inc. Details
2.3.2 Baxter International Inc. Major Business
2.3.3 Baxter International Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Product and Services
2.3.4 Baxter International Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Baxter International Inc. Recent Developments/Updates
2.4 ChemoCentryx Inc.
2.4.1 ChemoCentryx Inc. Details
2.4.2 ChemoCentryx Inc. Major Business
2.4.3 ChemoCentryx Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Product and Services
2.4.4 ChemoCentryx Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 ChemoCentryx Inc. Recent Developments/Updates
2.5 Dimerix Ltd
2.5.1 Dimerix Ltd Details
2.5.2 Dimerix Ltd Major Business
2.5.3 Dimerix Ltd Focal Segmental Glomerulosclerosis (FSGS) Treatment Product and Services
2.5.4 Dimerix Ltd Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Dimerix Ltd Recent Developments/Updates
2.6 Medtronic PLC
2.6.1 Medtronic PLC Details
2.6.2 Medtronic PLC Major Business
2.6.3 Medtronic PLC Focal Segmental Glomerulosclerosis (FSGS) Treatment Product and Services
2.6.4 Medtronic PLC Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Medtronic PLC Recent Developments/Updates
2.7 Pfizer Inc.
2.7.1 Pfizer Inc. Details
2.7.2 Pfizer Inc. Major Business
2.7.3 Pfizer Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Product and Services
2.7.4 Pfizer Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Pfizer Inc. Recent Developments/Updates
2.8 Mylan N.V.
2.8.1 Mylan N.V. Details
2.8.2 Mylan N.V. Major Business
2.8.3 Mylan N.V. Focal Segmental Glomerulosclerosis (FSGS) Treatment Product and Services
2.8.4 Mylan N.V. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Mylan N.V. Recent Developments/Updates
2.9 Amgen Inc.
2.9.1 Amgen Inc. Details
2.9.2 Amgen Inc. Major Business
2.9.3 Amgen Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Product and Services
2.9.4 Amgen Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Amgen Inc. Recent Developments/Updates
2.10 AstraZeneca plc
2.10.1 AstraZeneca plc Details
2.10.2 AstraZeneca plc Major Business
2.10.3 AstraZeneca plc Focal Segmental Glomerulosclerosis (FSGS) Treatment Product and Services
2.10.4 AstraZeneca plc Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 AstraZeneca plc Recent Developments/Updates
3 Competitive Environment: Focal Segmental Glomerulosclerosis (FSGS) Treatment by Manufacturer
3.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Manufacturer (2018-2023)
3.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue by Manufacturer (2018-2023)
3.3 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Focal Segmental Glomerulosclerosis (FSGS) Treatment by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Focal Segmental Glomerulosclerosis (FSGS) Treatment Manufacturer Market Share in 2022
3.4.2 Top 6 Focal Segmental Glomerulosclerosis (FSGS) Treatment Manufacturer Market Share in 2022
3.5 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market: Overall Company Footprint Analysis
3.5.1 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market: Region Footprint
3.5.2 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market: Company Product Type Footprint
3.5.3 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Region
4.1.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Region (2018-2029)
4.1.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Region (2018-2029)
4.1.3 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Average Price by Region (2018-2029)
4.2 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value (2018-2029)
4.3 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value (2018-2029)
4.4 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value (2018-2029)
4.5 South America Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value (2018-2029)
4.6 Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Type (2018-2029)
5.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Type (2018-2029)
5.3 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Application (2018-2029)
6.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Application (2018-2029)
6.3 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Average Price by Application (2018-2029)
7 North America
7.1 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Type (2018-2029)
7.2 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Application (2018-2029)
7.3 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country
7.3.1 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Country (2018-2029)
7.3.2 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Type (2018-2029)
8.2 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Application (2018-2029)
8.3 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country
8.3.1 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Country (2018-2029)
8.3.2 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Region
9.3.1 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Type (2018-2029)
10.2 South America Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Application (2018-2029)
10.3 South America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country
10.3.1 South America Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Country (2018-2029)
10.3.2 South America Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country
11.3.1 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Drivers
12.2 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Restraints
12.3 Focal Segmental Glomerulosclerosis (FSGS) Treatment Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Focal Segmental Glomerulosclerosis (FSGS) Treatment and Key Manufacturers
13.2 Manufacturing Costs Percentage of Focal Segmental Glomerulosclerosis (FSGS) Treatment
13.3 Focal Segmental Glomerulosclerosis (FSGS) Treatment Production Process
13.4 Focal Segmental Glomerulosclerosis (FSGS) Treatment Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Focal Segmental Glomerulosclerosis (FSGS) Treatment Typical Distributors
14.3 Focal Segmental Glomerulosclerosis (FSGS) Treatment Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

List of Tables
Table 1. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Competition Deep Dive Basic Information, Manufacturing Base and Competitors
Table 4. Competition Deep Dive Major Business
Table 5. Competition Deep Dive Focal Segmental Glomerulosclerosis (FSGS) Treatment Product and Services
Table 6. Competition Deep Dive Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Competition Deep Dive Recent Developments/Updates
Table 8. Beckman Coulter Inc. Basic Information, Manufacturing Base and Competitors
Table 9. Beckman Coulter Inc. Major Business
Table 10. Beckman Coulter Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Product and Services
Table 11. Beckman Coulter Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Beckman Coulter Inc. Recent Developments/Updates
Table 13. Baxter International Inc. Basic Information, Manufacturing Base and Competitors
Table 14. Baxter International Inc. Major Business
Table 15. Baxter International Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Product and Services
Table 16. Baxter International Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Baxter International Inc. Recent Developments/Updates
Table 18. ChemoCentryx Inc. Basic Information, Manufacturing Base and Competitors
Table 19. ChemoCentryx Inc. Major Business
Table 20. ChemoCentryx Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Product and Services
Table 21. ChemoCentryx Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. ChemoCentryx Inc. Recent Developments/Updates
Table 23. Dimerix Ltd Basic Information, Manufacturing Base and Competitors
Table 24. Dimerix Ltd Major Business
Table 25. Dimerix Ltd Focal Segmental Glomerulosclerosis (FSGS) Treatment Product and Services
Table 26. Dimerix Ltd Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Dimerix Ltd Recent Developments/Updates
Table 28. Medtronic PLC Basic Information, Manufacturing Base and Competitors
Table 29. Medtronic PLC Major Business
Table 30. Medtronic PLC Focal Segmental Glomerulosclerosis (FSGS) Treatment Product and Services
Table 31. Medtronic PLC Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Medtronic PLC Recent Developments/Updates
Table 33. Pfizer Inc. Basic Information, Manufacturing Base and Competitors
Table 34. Pfizer Inc. Major Business
Table 35. Pfizer Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Product and Services
Table 36. Pfizer Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Pfizer Inc. Recent Developments/Updates
Table 38. Mylan N.V. Basic Information, Manufacturing Base and Competitors
Table 39. Mylan N.V. Major Business
Table 40. Mylan N.V. Focal Segmental Glomerulosclerosis (FSGS) Treatment Product and Services
Table 41. Mylan N.V. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Mylan N.V. Recent Developments/Updates
Table 43. Amgen Inc. Basic Information, Manufacturing Base and Competitors
Table 44. Amgen Inc. Major Business
Table 45. Amgen Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Product and Services
Table 46. Amgen Inc. Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Amgen Inc. Recent Developments/Updates
Table 48. AstraZeneca plc Basic Information, Manufacturing Base and Competitors
Table 49. AstraZeneca plc Major Business
Table 50. AstraZeneca plc Focal Segmental Glomerulosclerosis (FSGS) Treatment Product and Services
Table 51. AstraZeneca plc Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. AstraZeneca plc Recent Developments/Updates
Table 53. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 54. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue by Manufacturer (2018-2023) & (USD Million)
Table 55. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 56. Market Position of Manufacturers in Focal Segmental Glomerulosclerosis (FSGS) Treatment, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 57. Head Office and Focal Segmental Glomerulosclerosis (FSGS) Treatment Production Site of Key Manufacturer
Table 58. Focal Segmental Glomerulosclerosis (FSGS) Treatment Market: Company Product Type Footprint
Table 59. Focal Segmental Glomerulosclerosis (FSGS) Treatment Market: Company Product Application Footprint
Table 60. Focal Segmental Glomerulosclerosis (FSGS) Treatment New Market Entrants and Barriers to Market Entry
Table 61. Focal Segmental Glomerulosclerosis (FSGS) Treatment Mergers, Acquisition, Agreements, and Collaborations
Table 62. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Region (2018-2023) & (K Units)
Table 63. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Region (2024-2029) & (K Units)
Table 64. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 65. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 66. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Average Price by Region (2018-2023) & (US$/Unit)
Table 67. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Average Price by Region (2024-2029) & (US$/Unit)
Table 68. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 69. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 70. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 71. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 72. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Average Price by Type (2018-2023) & (US$/Unit)
Table 73. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Average Price by Type (2024-2029) & (US$/Unit)
Table 74. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 75. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 76. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 77. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 78. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Average Price by Application (2018-2023) & (US$/Unit)
Table 79. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Average Price by Application (2024-2029) & (US$/Unit)
Table 80. North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 81. North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 82. North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 83. North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 84. North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Country (2018-2023) & (K Units)
Table 85. North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Country (2024-2029) & (K Units)
Table 86. North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 87. North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 88. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 89. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 90. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 91. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 92. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Country (2018-2023) & (K Units)
Table 93. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Country (2024-2029) & (K Units)
Table 94. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 95. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 96. Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 97. Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 98. Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 99. Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 100. Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Region (2018-2023) & (K Units)
Table 101. Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Region (2024-2029) & (K Units)
Table 102. Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 103. Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 104. South America Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 105. South America Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 106. South America Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 107. South America Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 108. South America Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Country (2018-2023) & (K Units)
Table 109. South America Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Country (2024-2029) & (K Units)
Table 110. South America Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 111. South America Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 112. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 113. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 114. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 115. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 116. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Region (2018-2023) & (K Units)
Table 117. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity by Region (2024-2029) & (K Units)
Table 118. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 119. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 120. Focal Segmental Glomerulosclerosis (FSGS) Treatment Raw Material
Table 121. Key Manufacturers of Focal Segmental Glomerulosclerosis (FSGS) Treatment Raw Materials
Table 122. Focal Segmental Glomerulosclerosis (FSGS) Treatment Typical Distributors
Table 123. Focal Segmental Glomerulosclerosis (FSGS) Treatment Typical Customers
List of Figures
Figure 1. Focal Segmental Glomerulosclerosis (FSGS) Treatment Picture
Figure 2. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value Market Share by Type in 2022
Figure 4. Drug Therapy Examples
Figure 5. Dialysis Examples
Figure 6. Kidney Transplant Examples
Figure 7. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value Market Share by Application in 2022
Figure 9. Primary FSGS Examples
Figure 10. Secondary FSGS Examples
Figure 11. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 12. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 13. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity (2018-2029) & (K Units)
Figure 14. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Average Price (2018-2029) & (US$/Unit)
Figure 15. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity Market Share by Manufacturer in 2022
Figure 16. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value Market Share by Manufacturer in 2022
Figure 17. Producer Shipments of Focal Segmental Glomerulosclerosis (FSGS) Treatment by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 18. Top 3 Focal Segmental Glomerulosclerosis (FSGS) Treatment Manufacturer (Consumption Value) Market Share in 2022
Figure 19. Top 6 Focal Segmental Glomerulosclerosis (FSGS) Treatment Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity Market Share by Region (2018-2029)
Figure 21. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value Market Share by Region (2018-2029)
Figure 22. North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 23. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 24. Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 25. South America Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 26. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value (2018-2029) & (USD Million)
Figure 27. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 28. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value Market Share by Type (2018-2029)
Figure 29. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Average Price by Type (2018-2029) & (US$/Unit)
Figure 30. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 31. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value Market Share by Application (2018-2029)
Figure 32. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Average Price by Application (2018-2029) & (US$/Unit)
Figure 33. North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 34. North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 35. North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity Market Share by Country (2018-2029)
Figure 36. North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value Market Share by Country (2018-2029)
Figure 37. United States Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 38. Canada Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Mexico Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 41. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 42. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity Market Share by Country (2018-2029)
Figure 43. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value Market Share by Country (2018-2029)
Figure 44. Germany Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. France Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. United Kingdom Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. Russia Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Italy Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 50. Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 51. Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity Market Share by Region (2018-2029)
Figure 52. Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value Market Share by Region (2018-2029)
Figure 53. China Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Japan Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Korea Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. India Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Southeast Asia Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Australia Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. South America Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 60. South America Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 61. South America Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity Market Share by Country (2018-2029)
Figure 62. South America Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value Market Share by Country (2018-2029)
Figure 63. Brazil Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. Argentina Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 66. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 67. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Sales Quantity Market Share by Region (2018-2029)
Figure 68. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value Market Share by Region (2018-2029)
Figure 69. Turkey Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Egypt Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Saudi Arabia Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. South Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Drivers
Figure 74. Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Restraints
Figure 75. Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Trends
Figure 76. Porters Five Forces Analysis
Figure 77. Manufacturing Cost Structure Analysis of Focal Segmental Glomerulosclerosis (FSGS) Treatment in 2022
Figure 78. Manufacturing Process Analysis of Focal Segmental Glomerulosclerosis (FSGS) Treatment
Figure 79. Focal Segmental Glomerulosclerosis (FSGS) Treatment Industrial Chain
Figure 80. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 81. Direct Channel Pros & Cons
Figure 82. Indirect Channel Pros & Cons
Figure 83. Methodology
Figure 84. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 局所分節性糸球体硬化症（FSGS）治療の世界市場2023-2029：薬物療法、透析、腎移植
  • 限局性結節性糸球体硬化症（FSGS）治療薬の世界市場2022-2028：錠剤、カプセル、その他
  • 伝染性軟属腫（MC）治療のグローバル市場2023：凍結療法、免疫調節療法、局所療法
  • 非定型奇形性ラブドイド腫瘍（ATRT）治療のグローバル市場2023：手術、化学療法、放射線療法、標的免疫療法
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR23AG11388 )"巣状分節性糸球体硬化症（FSGS）治療のグローバル市場2023：薬物治療、透析、腎移植" (英文：Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。